This association and its high frequency in AML‐MRC raises the possible role of ASXL1 as a surrogated molecular marker, which could facilitate the diagnosis of patients within this group, especially in the absence of other diagnostic criteria such as cytogenetic features, or a previous history of MDS or MDS/MPN; or when the assessment of multilineage dysplasia is morphologically difficult. This evidence concerns the gene ASXL1 and myeloproliferative neoplasm.